4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide has been researched along with Muscular Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bussey, RA; Eikenberry, SA; Rohlwing, JJ; Sluka, KA; Wilken, JM | 1 |
1 other study(ies) available for 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide and Muscular Diseases
| Article | Year |
|---|---|
Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Behavior, Animal; Benzamides; Chronic Disease; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Hydrochloric Acid; Hydrogen-Ion Concentration; Hyperalgesia; Injections, Spinal; Morphine; Muscular Diseases; Pain Threshold; Physical Stimulation; Piperazines; Rats; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2002 |